PLYMOUTH MEETING, PA [April 28, 2026] — The National Comprehensive Cancer Network ® (NCCN ®)—an alliance of leading cancer centers—has published a new book explaining the latest evidence and expert ...

A newly expanded prostate cancer drug could bring new hope to patients with a common form of the disease. Novartis, a Switzerland-based pharmaceutical company, announced on March 28 that the U.S. Food ...

While prognoses for prostate cancer patients were once measured in months, experts say that advances in treatment and diagnosis now improve survival by years. By Gina Kolata Prostate cancer experts ...

Talzenna plus Xtandi showed a 14-month survival improvement for HRR gene-mutated metastatic castration-resistant prostate cancer, supported by TALAPRO-2 trial data. Nubeqa approval for metastatic ...

Beyond the physical, a prostate cancer diagnosis carries significant emotional weight. Understanding this spectrum of ...

The American Cancer Society reports that about one in eight men will be diagnosed with prostate cancer in their lifetime. The average age of men who get diagnosed is 67. Today, less than 1% of the 3.5 ...

Less is more in the case of this cancer treatment. The most common form of cancer among men in the US, after skin cancer, prostate cancer often comes with traditional treatments that cause difficult ...

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, UVA Cancer Center researchers have discovered. Based on new findings in ...

Researchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new gene expression signature within tumors that can help identify patients with ...

I am a prostate cancer patient and a board-certified health care chaplain. I’ve served patients from every end of the spectrum. And I’m living with hormone-sensitive, high-grade (Gleason 9) prostate ...

Only men with a specific gene variant and a family history of certain cancers should be screened, experts have said.

Survivorship in metastatic prostate cancer is seen as chronic management, focusing on quality of life through physical and emotional management. Carotuximab combined with Erleada shows a favorable ...